ArticleJournal of gastrointestinal cancer2026
The Vascular Density/Angiogenesis Marker CD31/PECAM1 does not Correlate with Overall Survival in Neuroendocrine Tumors.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammasome-associated pyroptosis and tumor angiogenesis in prostate cancer.Iranian journal of basic medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NENs) are rare cancers. CD31/PECAM1 is an adhesion molecule that modulates endothelial cell-to-cell contact. Increased CD31 expression is a marker for tumor growth, and cancer aggressiveness. The purpose of this study was to better understand the prognostic value of CD31 expression in primary and metastatic NEN tumors in terms of correlations with overall survival and pathological metrics, tumor grade, and tumor primary/metastatic location. As NENs are highly vascular tumors, the hypothesis is that CD31 staining is an important prognostic biomarker and target. This is based on prior correlations between CD31 staining and 3-year recurrence-free survival in pancreas NENs.
methodsNEN tumors, surgically removed within our dedicated multi state southern regional neuroendocrine program, are routinely stained for CD31. Quantification of CD31 staining was performed by staff pathologists and documented in the pathology report within the patient medical record and stored in the rare cancer program RedCap database. The database covers surgical activity between 2004 and 2024. The database was queried for NET patients with quantified CD31 levels (number of positive vessels per high power field (HPF)) in primary or metastatic NEN tumors. CD31 levels were cross referenced against demographics, tumor grade, primary and metastatic tumor location, and overall survival.
resultsNine hundred and thirteen NET patients were identified. Primary tumor: Small Bowel (74%), Pancreas (15%), Lung (2%), Stomach (5%), & Rectum (4%). DEMOGRAPHICS: Female 59±8.6%, Non-Hispanic 93.4±2%, White/Caucasian 70.4±14.3%, & Black/African American 21.6±16%. Grade: G1 45±8%, G2 44±3.6, G3 11±5.8%. There were no statistical differences in CD31 staining levels (cells/HPF) between (1) NEN tumors from small bowel (33 ± 17), pancreas (39.7 ± 34), lung (44 ± 27), stomach (39 ± 27), and rectum (32 ± 19) (p > 0.05), (2) tumor grade (G1. 31 ± 16; G2. 30 ± 16; and G3. 25 ± 12) (p > 0.05), (3) between matched primary and metastatic tumors (lymph node metastasis. 29 ± 16 vs. primary tumor 30 ± 14 (p = 0.46); liver metastasis 30 ± 18 vs. primary tumor 32 ± 17 (p = 0.17), & (4) no correlation between CD31 staining and overall survival (r = 0.01).
conclusionNEN tumors are highly vascularized and consistently positive for CD31. Despite reports that CD31/PACAM1 is important to cell adhesion and tumor phenotype, there was no identifiable measurable impact of high CD31 levels on NEN. Nor was there a prognostic clinical value for CD31 staining quantification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.